1. Belgium Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA

4.12
EUR
+0.23
(+5.78%)
191.52MMarket Cap
Mar 17Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
- -
- -
0.01
0.12
0.03
0.07
0.3
0.26
- -
Basic EPS, GAAP
- -
-0.16
-0.25
-0.23
-0.33
-0.45
-0.44
-0.55
-0.23
-0.23
- -
Free Cash Flow per Basic Share
- -
-0.19
-0.23
-0.25
-0.24
-0.48
-0.51
-0.48
-0.27
-0.27
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.09
-0.18
-0.1
-0.43
2.29
1.86
1.93
1.4
1.15
0.95
0.95
Tangible Book Value per Share
-0.14
-0.34
-0.26
-0.52
2.19
1.75
1.8
1.26
1.01
0.74
0.74
Basic Weighted Avg Shares
24
24
24
24
22
26
27
28
28
28
28
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
3
1
2
8
7
- -
Operating Margin (%)
- -
-1,814.55
-6,009.89
-5,795.6
-3,174.86
-334.24
-1,278.67
-759.27
-75.3
-106.97
- -
Depreciation Expense
- -
- -
- -
3
1
- -
- -
- -
1
1
- -
Net Income, GAAP
- -
-4
-6
-5
-7
-12
-12
-15
-6
-6
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1,745.07
-6,363.74
-5,904.4
-4,082.86
-374
-1,322.89
-736.94
-74.98
-87.89
- -
Working Capital
-1
-1
1
-12
64
39
44
29
23
15
15
LT Debt
2
7
9
- -
8
- -
1
2
1
1
1
Total Equity
-2
-4
-4
-10
59
48
54
39
32
26
26
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-21.62
-23.35
-33.08
-17.81
-21.61
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
190
176
192

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
30
24
20
Cash, Cash Equivalents & STI
24
19
14
Accounts Receivable, Net
5
4
5
Inventories
- -
- -
- -
Total Current Liabilities
7
6
5
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-13.87%
-17.63%
Free Cash Flow
- -
20.86%
1.71%
Net Income, GAAP
- -
7.03%
-0.13%
Sales/Revenue/Turnover
- -
404.12%
-14.79%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
8
2025
- -
- -
7

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.55
2024
- -
- -
-0.23
2025
- -
- -
-0.23

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Stijn van Rompay
Full Time Employees
55
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Boulevard Gustave Kleyer 17 Liege WA Belgium 4000
IPO Date
Jun 29, 2020
Website
hyloris.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hyloris Pharmaceuticals SA operates as a specialized biopharmaceutical company, concentrating on the development and delivery of innovative, value-added medicines to address significant unmet medical needs. The firm’s comprehensive portfolio spans critical areas such as cardiovascular health, pain management, oncology, women's health, and central nervous system disorders. Hyloris employs a strategy of reformulating and repurposing existing pharmaceutical compounds, frequently utilizing established regulatory pathways like the FDA's 505(b)(2) route, to accelerate market entry and enhance patient outcomes. Its commercial-stage offerings include Sotalol IV for atrial fibrillation, Maxigesic® IV (known as Combogesic® IV in the U.S.) for post-operative pain, and Podofilox Gel for certain dermatological conditions. With a robust pipeline currently featuring over two dozen product candidates, Hyloris continues to expand its reach through strategic collaborations and recent commercial launches, including Maxigesic® IV in the U.S. Hyloris Pharmaceuticals SA was founded in 2012 and maintains its headquarters in Liège, Belgium, with Stijn Van Rompay recently appointed as its sole Chief Executive Officer.